<p>Alzheimer’s disease is the most common type of dementia, a disorder of progressively worsening memory and other thinking abilities. It rose up in the ranks of leading causes of death over the past several decades. It can also limit the duration of a working career, create uncertainty in the financial planning for retirement and rob patients of enjoyment and happiness in the final years. An effective treatment against this disease could give back to the patient the decision when to retire and improve quality of life in advanced age. </p>
<p>Now, scientists at the Alzheimer’s Center at Temple at the Lewis Katz School of Medicine at Temple University are on the trail of a promising new therapeutic target – ABCA7, a protein known to protect from Alzheimer’s disease. The study, <u><a href="https://pubmed.ncbi.nlm.nih.gov/37681876/">published online in the journal <em>Cells</em></a></u>, uncovers new information about the relationship between ABCA7, cholesterol, and inflammation in human brain cells.</p>